RESUMEN
Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AICs). Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase approved for the treatment of relapsed CLL and CLL with del(17p). The effect of ibrutinib treatment on the incidence of AIC is currently unknown. We reviewed medical records of 301 patients treated with ibrutinib, as participants in therapeutic clinical trials at The Ohio State University Comprehensive Cancer Center between July 2010 and July 2014. Subjects were reviewed with respect to past history of AIC, and treatment-emergent AIC cases were identified. Before starting ibrutinib treatment, 26% of patients had experienced AIC. Information was available for a total of 468 patient-years of ibrutinib exposure, during which there were six cases of treatment-emergent AIC. This corresponds to an estimated incidence rate of 13 episodes for every 1000 patient-years of ibrutinib treatment. We further identified 22 patients receiving therapy for AIC at the time ibrutinib was started. Of these 22 patients, 19 were able to discontinue AIC therapy. We found that ibrutinib treatment is associated with a low rate of treatment-emergent AIC. Patients with an existing AIC have been successfully treated with ibrutinib and subsequently discontinued AIC therapy.
Asunto(s)
Anemia Hemolítica Autoinmune/inducido químicamente , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Púrpura Trombocitopénica Idiopática/inducido químicamente , Pirazoles/efectos adversos , Pirimidinas/efectos adversos , Adenina/análogos & derivados , Adulto , Agammaglobulinemia Tirosina Quinasa , Anciano , Anciano de 80 o más Años , Anemia Hemolítica Autoinmune/epidemiología , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Piperidinas , Púrpura Trombocitopénica Idiopática/epidemiologíaAsunto(s)
Suero Antilinfocítico/administración & dosificación , Acondicionamiento Pretrasplante/métodos , Adulto , Anciano , Animales , Difenhidramina/administración & dosificación , Esquema de Medicación , Famotidina/administración & dosificación , Femenino , Humanos , Inmunosupresores/uso terapéutico , Masculino , Metilprednisolona/administración & dosificación , Persona de Mediana Edad , Proyectos Piloto , Conejos , Estudios Retrospectivos , Resultado del TratamientoAsunto(s)
Antineoplásicos/administración & dosificación , Ácidos Borónicos/administración & dosificación , Inmunosupresores/administración & dosificación , Mieloma Múltiple/terapia , Trasplante de Células Madre de Sangre Periférica , Pirazinas/administración & dosificación , Talidomida/análogos & derivados , Talidomida/administración & dosificación , Adulto , Anciano , Bortezomib , Femenino , Estudios de Seguimiento , Humanos , Lenalidomida , Masculino , Persona de Mediana Edad , Mieloma Múltiple/mortalidad , Estudios Retrospectivos , Trasplante AutólogoRESUMEN
The evaluation of patients for hematopoietic stem cell transplantation is a complex process. The decision to recommend transplantation is not simply dependent on patient diagnosis; instead it is a specialized analytic decision process intricately dependent on a number of variables including patient age, performance status, medical comorbidities, family support structure, socioeconomic viability and motivation to participate in self-care, to name a few. The process of pre-transplant patient evaluation has substantial variability across different transplant centers, owing to lack of formal published guidelines. This review summarizes the process of pre-transplant patient evaluation and workup, and aims to describe components of a well-organized and evidenced-based patient selection process for SCT.